BG
TEVA icon

Bellevue Group’s Teva Pharmaceuticals TEVA Stock Holding History

Bellevue Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
345,899
+95,817
+38% +$3.19M 0.25% 65
2026
Q1 		$7.53M Sell
250,082
-77,781
-24% -$2.5M 0.18% 64
2025
Q4 		$10.2M Sell
327,863
-96,193
-23% -$2.37M 0.19% 61
2025
Q3 		$8.57M Buy
424,056
+2,555
+0.6% +$44.9K 0.18% 64
2025
Q2 		$7.06M Buy
421,501
+392,571
+1,357% +$6.33M 0.16% 73
2025
Q1 		$445K Sell
28,930
-31,668
-52% -$566K 0.01% 120
2024
Q4 		$1.34M Sell
60,598
-10,223
-14% -$186K 0.03% 112
2024
Q3 		$1.28M Sell
70,821
-83,949
-54% -$1.47M 0.02% 113
2024
Q2 		$2.52M Buy
154,770
+12,557
+9% +$193K 0.04% 109
2024
Q1 		$2.01M Buy
+142,213
New +$1.79M 0.03% 108
2020
Q2 		– Sell
-303,000
Closed -$2.72M – 225
2020
Q1 		$2.72M Buy
303,000
+37,000
+14% +$379K 0.05% 124
2019
Q4 		$2.61M Buy
266,000
+116,000
+77% +$1.04M 0.04% 125
2019
Q3 		$1.03M Buy
+150,000
New +$1.15M 0.02% 143
2019
Q1 		– Sell
-60,000
Closed -$925K – 148
2018
Q4 		$925K Hold
60,000
– – 0.06% 119
2018
Q3 		$1.29M Sell
60,000
-30,000
-33% -$696K 0.08% 118
2018
Q2 		$2.19M Hold
90,000
– – 0.19% 85
2018
Q1 		$1.54M Sell
90,000
-581,940
-87% -$11.4M 0.15% 93
2017
Q4 		$12.7M Buy
671,940
+90,000
+15% +$1.35M 1.33% 28
2017
Q3 		$10.2M Buy
581,940
+296,611
+104% +$6.67M 1.07% 33
2017
Q2 		$9.48M Sell
285,329
-80,843
-22% -$2.5M 1.12% 35
2017
Q1 		$11.8M Buy
366,172
+131,182
+56% +$4.48M 1.57% 23
2016
Q4 		$8.52M Buy
234,990
+47,800
+26% +$1.91M 1.74% 21
2016
Q3 		$8.61M Sell
187,190
-42,000
-18% -$2.19M 1.56% 23
2016
Q2 		$11.5M Buy
229,190
+33,900
+17% +$1.8M 2.17% 12
2016
Q1 		$10.4M Buy
+195,290
New +$11.5M 1.9% 13

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bellevue Group's TEVA Position: Q2 2026 in Review

Bellevue Group increased its Teva Pharmaceuticals (TEVA) stake by 38% in Q2 2026, buying an estimated $3.19M and bringing the position to 345,899 shares worth $11.7M. The position accounts for 0.25% of the portfolio, ranked #65.

Bellevue Group first reported a position in TEVA in Q1 2016 and has held it in 25 quarters since. The position peaked at $12.7M in Q4 2017. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Bellevue Group held 345,899 shares of Teva Pharmaceuticals worth $11.7M as of Q2 2026.
  • Bellevue Group bought 95,817 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.19M.
  • Teva Pharmaceuticals made up 0.25% of Bellevue Group's portfolio in Q2 2026, its #65 holding.
  • Bellevue Group first reported a position in Teva Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
  • Bellevue Group's Teva Pharmaceuticals position peaked at $12.7M in Q4 2017.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.